We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Holly
Hogan
holly.hogan@rmh.nhs.uk
Jeane
Guevara
jeane.guevara@rmh.nhs.uk
Kathie
Wong
Kathie.wong@ncic.nhs.uk
Diseases of male genital organsMalignant neoplasms of male genital organs
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Men with prostate cancer undergoing radiotherapy often have co-existing lower urinary tract symptoms (LUTS) secondary to prostate hyperplasia. These symptoms can preclude radiotherapy treatment or exacerbate complications during and post treatment. Currently, patients are formally assessed in a dedicated LUTS clinic and patients with symptoms may be offered further LUTS treatment including lifestyle advice, medication and surgery. Patients with the most severe symptoms are offered a transurethral resection of prostate (TURP). This is an operation which involves a general / spinal anaesthetic and average length of stay of two days. There are side effects associated with surgery and radiotherapy combined needs to be postponed 4-6 weeks to allow patients to recover from surgery.
UroLift offers a minimally invasive alternative to TURP which can be performed as a day case with a 0.2 day length of stay. It is a NICE approved product widely accepted as treatment for Benign Prostate Hpyerplasia (BPH). We aim to evaluate the clinical outcomes, safety, feasibility and tolerability of Urolift as a treatment for LUTS for men undergoing prostate radiotherapy.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Interventional type: Surgery;
You can take part if:
You may not be able to take part if:
1) Extensive locally advanced disease 2) Unfavourable anatomical features (e.g. large middle lobe, for UroLift this requires advanced techniques that have not been fully evaluated in the benign setting) 3) Prostates over 100g (as per manufacturer’s guidelines) 4) Co-morbidities precluding surgical intervention 5) Prior prostate cancer treatment (including radical prostatectomy, focal therapy i.e. brachytherapy / high intensity focal ultrasound) 6) Prior surgical intervention for benign prostatic hyperplasia (including prior UroLift / TURP / other prostate de-obstructing procedures) 7) Urinary symptoms not due to prostatic enlargement as primary cause (i.e. neurological disease) 8) Patients with complications of prostate enlargement including catheter dependent retention, recurrent urinary tract infections, bladder stones, obstructive uropathy 9) Urinary incontinence due to an incompetent sphincter 10) Co-existing gross haematuria 11) Current active urinary tract infection
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Jeane
Guevara
jeane.guevara@rmh.nhs.uk
Holly
Hogan
holly.hogan@rmh.nhs.uk
Kathie
Wong
Kathie.wong@ncic.nhs.uk
The study is sponsored by THE ROYAL MARSDEN NHS FOUNDATION TRUST and funded by NIHR Central Commissioning Facility (CCF) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 54250
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
